TriSalus Life Sciences Q3 revenue misses estimates

Overview

• US oncology medtech firm's Q3 revenue rose 11% yr/yr but missed analyst expectations

• Company narrowed operating and adjusted EBITDA losses, helped by improved gross margins and lower R&D costs

• 2026 revenue guidance revised to $46 mln-$48 mln, implying 2%-6% growth over 2025

Outlook

• TriSalus revises 2026 revenue guidance to $46 mln-$48 mln, up 2%-6% year over year

• Company expects continued growth in 2027, citing expanded commercial footprint and new product launches

• CMS finalizes expanded reimbursement for PEDD procedures, effective January 2027

Result Drivers

• TRINAV SALES - Co said Q3 revenue growth was mainly driven by higher TriNav system sales

• LOWER UNIT COSTS - Co attributed improved gross margins to reduced cost per TriNav unit

• COMMERCIAL EXPANSION - Co expanded its commercial organization, though team productivity ramped slower than expected

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for TriSalus Life Sciences Inc is $9.00, about 179.5% above its November 9 closing price of $3.22

Reuters Recommended Reads

• Nov 9 - Oncology firm Delcath Systems' Q3 revenue beats on Hepzato growth

• Nov 9 - Abeona Therapeutics Q3 profit beats expectations on treatment network expansion

• Nov 9 - Medical tech firm NeurAxis' Q3 revenue jumps on broader insurance coverage

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)